Frederique Ph.D. Menzaghi - Feb 25, 2022 Form 4 Insider Report for Cara Therapeutics, Inc. (CARA)

Signature
/s/Darren DeStefano, Attorney-in-Fact
Stock symbol
CARA
Transactions as of
Feb 25, 2022
Transactions value $
-$21,753
Form type
4
Date filed
3/1/2022, 03:16 PM
Previous filing
Dec 21, 2021
Next filing
Apr 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CARA Common Stock Award $0 +20K +13.01% $0.00 174K Feb 25, 2022 Direct F1
transaction CARA Common Stock Sale -$21.8K -2.11K -1.22% $10.29 172K Feb 25, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CARA Employee Stock Option (Right to Buy) Award $0 +40K $0.00 40K Feb 25, 2022 Common Stock 40K $10.46 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of February 25, 2023, February 25, 2024 and February 25, 2025, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.
F2 This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs reported in the Form 4 filed with the Securities and Exchange Commission on August 26, 2021, and does not represent a discretionary trade by the Reporting Person.
F3 The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on March 25, 2022, in each case subject to the Reporting Person's continued service as of each such date.